These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 21111736)
41. [l-dopa treatment of Parkinson's syndrome and mechanism of action of neuroleptics]. Degkwitz R Med Klin; 1969 Aug; 64(33):1451-6. PubMed ID: 4896563 [No Abstract] [Full Text] [Related]
42. Is it Parkinson's disease? Hely M Aust Fam Physician; 1992 Oct; 21(10):1411-6. PubMed ID: 1444967 [TBL] [Abstract][Full Text] [Related]
43. MPTP and the aetiology of Parkinson's disease. Clinical implications. London, June 27, 1985. J Neural Transm Suppl; 1986; 20():1-81. PubMed ID: 3489069 [No Abstract] [Full Text] [Related]
44. Benefit/risk ratio of statins in primary prevention. Reidenberg MM Clin Pharmacol Ther; 2008 Mar; 83(3):498-500. PubMed ID: 17538549 [No Abstract] [Full Text] [Related]
46. R-(-)-deprenyl as a possible protective agent in Parkinson's disease. Tetrud JW; Langston JW J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606 [TBL] [Abstract][Full Text] [Related]
47. Benefits of statins in cerebrovascular disease. Di Napoli M Curr Opin Investig Drugs; 2004 Mar; 5(3):295-305. PubMed ID: 15083596 [TBL] [Abstract][Full Text] [Related]
48. Statins, fracture risk, and bone remodeling. Luisetto G; Camozzi V J Endocrinol Invest; 2009; 32(4 Suppl):32-7. PubMed ID: 19724164 [TBL] [Abstract][Full Text] [Related]
51. Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database. Liu G; Sterling NW; Kong L; Lewis MM; Mailman RB; Chen H; Leslie D; Huang X Mov Disord; 2017 Jun; 32(6):913-917. PubMed ID: 28370314 [TBL] [Abstract][Full Text] [Related]
52. Statins and postoperative delirium. Marcantonio ER CMAJ; 2008 Sep; 179(7):627-8. PubMed ID: 18809885 [No Abstract] [Full Text] [Related]
53. Linking statins and lipids in Parkinson's disease. Ng ASL; Tan EK Mov Disord; 2017 Jun; 32(6):807-809. PubMed ID: 28556203 [No Abstract] [Full Text] [Related]
54. Glutathione transferase polymorphism and Parkinson's disease. Paolini M; Biagi GL; Cantelli-Forti G Lancet; 1999 Jan; 353(9146):71-2. PubMed ID: 10023978 [No Abstract] [Full Text] [Related]
55. Statins and the risk of Parkinson disease: an update on the controversy. Becker C; Meier CR Expert Opin Drug Saf; 2009 May; 8(3):261-71. PubMed ID: 19366342 [TBL] [Abstract][Full Text] [Related]
56. MHRA reviews evidence on statins. Nurs Times; 2014 Jun 11-17; 110(24):4. PubMed ID: 25007484 [No Abstract] [Full Text] [Related]
57. Statins and venous thromboembolism: the jury is still out. Paraskevas KI; Nicolaides AN; Mikhailidis DP Angiology; 2013 Oct; 64(7):489-91. PubMed ID: 23990643 [No Abstract] [Full Text] [Related]
58. Statins use increases the risk of urinary tract cancer: preliminary results of a nationwide population-based case-control study. Kok VC; Horng JT; Agustriawan D Asia Pac J Clin Oncol; 2013 Jun; 9(2):190-1. PubMed ID: 23051154 [No Abstract] [Full Text] [Related]
59. Age, statin use, and the risk for incident Parkinson disease. Andrade C Arch Neurol; 2012 Oct; 69(10):1381; author reply 1381. PubMed ID: 23044596 [No Abstract] [Full Text] [Related]